Halozyme Therapeutics: Q4 Earnings Insights

Comments
Loading...

Halozyme Therapeutics HALO reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:01 PM.

Here's what investors need to know about the announcement.

Earnings

Halozyme Therapeutics missed estimated earnings by 1.2%, reporting an EPS of $0.82 versus an estimate of $0.83.

Revenue was up $48.54 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.02 which was followed by a 10.04% increase in the share price the next day.

Here's a look at Halozyme Therapeutics's past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 0.73 0.63 0.48 0.47
EPS Actual 0.75 0.74 0.47 0.48
Revenue Estimate 222.63M 199.32M 175.51M 192.05M
Revenue Actual 216.03M 221.04M 162.14M 181.50M

To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

HALO Logo
HALOHalozyme Therapeutics Inc
$58.82-4.01%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
93.25
Growth
-
Quality
94.36
Value
16.92
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: